TY - JOUR
T1 - [18F]FDG-PET/CT in Staphylococcus aureus bacteremia
T2 - a systematic review
AU - Buis, D. T. P.
AU - Sieswerda, E.
AU - Kouijzer, I. J. E.
AU - Huynh, W. Y.
AU - Burchell, G. L.
AU - Berrevoets, M. A. H.
AU - Prins, J. M.
AU - Sigaloff, K. C. E.
N1 - Publisher Copyright: © 2022, The Author(s).
PY - 2022/12/1
Y1 - 2022/12/1
N2 - Objectives: [18F]FDG-PET/CT is used for diagnosing metastatic infections in Staphylococcus aureus bacteremia (SAB) and guidance of antibiotic treatment. The impact of [18F]FDG-PET/CT on outcomes remains to be determined. The aim of this systematic review was to summarize the effects of [18F]FDG-PET/CT on all-cause mortality and new diagnostic findingsin SAB. Methods: We systematically searched PubMed, EMBASE.com, Web of Science, and Wiley’s Cochrane library from inception to 29 January 2021. Eligible studies were randomized controlled trials, clinically controlled trials, prospective and retrospective cohort studies, and case–control studies investigating the effects of [18F]FDG-PET/CT in hospitalized adult patients with SAB. We excluded studies lacking a control group without [18F]FDG-PET/CT. Risk of bias was assessed using the ROBINS-I tool and certainty of evidence using the GRADE approach by two independent reviewers. Results: We identified 1956 studies, of which five were included in our qualitative synthesis, including a total of 880 SAB patients. All studies were non-randomized and at moderate or serious risk of bias. Four studies, including a total of 804 patients, reported lower mortality in SAB patients that underwent [18F]FDG-PET/CT. One study including 102 patients reported more detected metastatic foci in the participants in whom [18F]FDG-PET/CT was performed. Discussion: We found low certainty of evidence that [18F]FDG-PET/CT reduces mortality in patients with SAB. This effect is possibly explained by a higher frequency of findings guiding optimal antibiotic treatment and source control interventions.
AB - Objectives: [18F]FDG-PET/CT is used for diagnosing metastatic infections in Staphylococcus aureus bacteremia (SAB) and guidance of antibiotic treatment. The impact of [18F]FDG-PET/CT on outcomes remains to be determined. The aim of this systematic review was to summarize the effects of [18F]FDG-PET/CT on all-cause mortality and new diagnostic findingsin SAB. Methods: We systematically searched PubMed, EMBASE.com, Web of Science, and Wiley’s Cochrane library from inception to 29 January 2021. Eligible studies were randomized controlled trials, clinically controlled trials, prospective and retrospective cohort studies, and case–control studies investigating the effects of [18F]FDG-PET/CT in hospitalized adult patients with SAB. We excluded studies lacking a control group without [18F]FDG-PET/CT. Risk of bias was assessed using the ROBINS-I tool and certainty of evidence using the GRADE approach by two independent reviewers. Results: We identified 1956 studies, of which five were included in our qualitative synthesis, including a total of 880 SAB patients. All studies were non-randomized and at moderate or serious risk of bias. Four studies, including a total of 804 patients, reported lower mortality in SAB patients that underwent [18F]FDG-PET/CT. One study including 102 patients reported more detected metastatic foci in the participants in whom [18F]FDG-PET/CT was performed. Discussion: We found low certainty of evidence that [18F]FDG-PET/CT reduces mortality in patients with SAB. This effect is possibly explained by a higher frequency of findings guiding optimal antibiotic treatment and source control interventions.
KW - Adult
KW - Bacteremia
KW - Bacteremia/diagnostic imaging
KW - Fluorodeoxyglucose F18
KW - Humans
KW - Positron Emission Tomography Computed Tomography
KW - Prospective Studies
KW - Randomized Controlled Trials as Topic
KW - Retrospective Studies
KW - Staphylococcus aureus
KW - Systematic review
KW - [18F]FDG-PET/CT
UR - http://www.scopus.com/inward/record.url?scp=85127062654&partnerID=8YFLogxK
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85127062654&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/35331165
U2 - https://doi.org/10.1186/s12879-022-07273-x
DO - https://doi.org/10.1186/s12879-022-07273-x
M3 - Article
C2 - 35331165
SN - 1471-2334
VL - 22
JO - BMC Infectious Diseases
JF - BMC Infectious Diseases
IS - 1
M1 - 282
ER -